RSS Feed Print
Montelukast AKA Singulair used for Mild Dementia / Alzheimers Treatment
Michael King
Posted: Tuesday, April 9, 2019 11:56 AM
Joined: 4/9/2019
Posts: 3

Hello everyone,

I would like to start a conversation about using Montelukast to treat mild to moderate dementia & alzheimers. I believe a lot of people are not aware of this treatment option. But those who are aware of it and have been using it or have used it, it would be great if you could post your results here for others to read.

Being Montelukast is an already prescribed drug and approved by the FDA, your doctor  can prescribe this under the off-label rules. If they will not do that, then let them know under the new "Right to Try" law that was signed into law federally, if a drug is in a phase II FDA trial, in which Montelukast is, by the company Intelgenx, then it qualifies for, Right to Try. That should make them more confident in off-label prescribing Montelukast for dementia / alzheimers.

Here is a couple of links of information regarding using Montelukast for treatment.

Latest exhibit of Phase I completed trial and current ongoing Phase II Trial

See page 3 of this article which shows a major improvement in MMSE score after 2 months

Dr Rozin Case study with multiple patients using Montelukast treatment.

Bottom line if you know someone suffering from this horrible disease, this is one treatment that should be considered immediately. 

Lets get this information out there!

Michael King

Posted: Tuesday, April 9, 2019 12:51 PM
Joined: 4/9/2019
Posts: 1

Hi.   My sister has been taking singular for years for asthma.  I never knew it could help ad.  She has frontal lobe ad and can't see any longer due to ad.  She has an appt with Univ of Texas Briggs Alzheimer's center next month.  I hope they can help with stem cells or clin trials.  She's 59 with early onset. A nurse for 15 yrs.  God I hate to lose her
Posted: Friday, June 28, 2019 9:37 PM
Joined: 2/17/2019
Posts: 380

NearInfraRed therapy has been found to be useful in treating Macular Degeneration, in addition to Alzheimers.


Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease

Daniel M. Johnstone1, Cécile Moro2, Jonathan Stone1, Alim-Louis Benabid2 and John Mitrofanis2*
  • 1Department of Physiology, University of Sydney, Sydney, NSW, Australia
  • 2University Grenoble Alpes, CEA, LETI, CLINATEC, MINATEC Campus, Grenoble, France
  • 3Department of Anatomy, University of Sydney, Sydney, NSW, Australia

Alzheimer's and Parkinson's disease are the two most common neurodegenerative disorders. They develop after a progressive death of many neurons in the brain. Although therapies are available to treat the signs and symptoms of both diseases, the progression of neuronal death remains relentless, and it has proved difficult to slow or stop. Hence, there is a need to develop neuroprotective or disease-modifying treatments that stabilize this degeneration. Red to infrared light therapy (λ = 600–1070 nm), and in particular light in the near infrared (NIr) range, is emerging as a safe and effective therapy that is capable of arresting neuronal death. Previous studies have used NIr to treat tissue stressed by hypoxia, toxic insult, genetic mutation and mitochondrial dysfunction with much success. Here we propose NIr therapy as a neuroprotective or disease-modifying treatment for Alzheimer's and Parkinson's patients.



2014 May;122:50-3. doi: 10.1016/j.exer.2014.02.023. Epub 2014 Mar 12.

Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP.


Progressive accumulation of age related mitochondrial DNA mutations reduce ATP production and increase reactive oxygen species output, leading to oxidative stress, inflammation and degradation. The pace of this is linked to metabolic demand. The retina has the greatest metabolic demand and mitochondrial density in the body and displays progressive age related inflammation and marked cell loss. Near infra-red (670 nm) is thought to be absorbed by cytochrome c oxidase (COX), a key element in mitochondrial respiration and it has been demonstrated that it improves mitochondrial membrane potentials in aged eyes. It also significantly reduces the impact of experimental pathology and ameliorates age related retinal inflammation. We show ATP decline with ageing in mouse retina and brain. Also, in these tissues that ATP is significantly increased by 670 nm exposure in old mice. In the retina this was associated with increased COX and reduced acrolein expression. Acrolein, being a free radical marker of retinal oxidative stress, is up regulated in Alzheimer's and retinal degeneration. This is the first demonstration of ATP manipulation in vivo and may provide a simple non-invasive route to combating age related tissue decline.


ageing; mitochondrial DNA; photoreceptor

PMID: 24631333 DOI: 10.1016/j.exer.2014.02.023
[Indexed for MEDLINE] Free full text

Posted: Saturday, June 29, 2019 7:51 PM
Joined: 1/25/2018
Posts: 752

Thanks for the info RE: Right to Try. Other than that, search posts by Larrytherunner. He has been an advocate for this therapy for some time and has posted details in several treads.